Kornimate/medical-research-clean huggingface dataset:
a study of modified mrna vaccines in healthy adults

Conditions: SARS-CoV-2; Seasonal Influenza; Respiratory Syncytial Virus; Cytomegalovirus

Summary: the main goal of this study is to evaluate the safety, reactogenicity, and immunogenicity of study vaccines.


Eligibility criteria:
inclusion criteria: * adults 18 to 75 years of age at the time of consent (screening visit) who, in the opinion of the investigator, are in good health based on review of medical history and physical examination performed at screening. for mrna-1647 study arms, adults 18 to \<50 years of age at the time of consent (screening visit) who, in the opinion of the investigator, are in good health based on review of medical history and physical examination performed at screening. * body mass index (bmi) of 18 kilograms (kg)/square meter (m\^2) to 35 kg/m\^2 (inclusive) at the screening visit. exclusion criteria: * participant has had close contact to someone with confirmed sars-cov-2, respiratory syncytial virus (rsv), or influenza infection in the past 14 days prior to the screening visit. * severe allergic reaction to any component of the fluad vaccine (active comparator), including egg protein, or after a previous dose of any influenza vaccine. * participant has received systemic immunosuppressants or immune-modifying drugs for \>14 days in total within 6 months prior to screening (to include any systemic corticosteroids) or is anticipating the need for immunosuppressive treatment at any time during participation in the study. * participant plans to receive any licensed or authorized vaccine, including covid-19 influenza vaccines, within 28 days before or after any study injection. * participant has received a nh 2021 - 2022 or 2022-2023 seasonal influenza vaccine or any other influenza vaccine, or an experimental rsv or cytomegalovirus (cmv) vaccine, within 6 months prior to study day 1, and/or has not completed a primary vaccination series for covid-19. * participant has received an authorized or approved covid-19 vaccine within 4 months prior to day 1, and/or has not completed a primary vaccination series for covid-19. * participant had a laboratory-confirmed infection with influenza or rsv within 6 months prior to day 1, or sars-cov-2 within 4 months of day 1. sars-cov-2 infection confirmed with self-administered, authorized or approved rapid antigen test is acceptable. * participant has donated ≥450 milliliters (ml) of blood products within 28 days prior to the screening visit or plans to donate blood products during the study. * participated in an interventional clinical study within 28 days prior to the screening visit based on the medical history interview or plans to do so while participating in this study until 12 months after their last study vaccination. other inclusion and exclusion criteria may apply.

Keywords: mrna-1273 mrna-1273 vaccine sars-cov-2 sars-cov-2 vaccine coronavirus virus diseases messenger rna covid-19 covid-19 vaccine moderna influenza vaccine mrna-1010 mrna-1345 respiratory syncytial virus rsv seropositive vaccines mrna-1647 cytomegalovirus cmv cytomegalovirus vaccine cytomegalovirus infections
upper extremity dysfunction post radial percutaneous coronary intervention

Conditions: Upper Extremity Dysfunction

Summary: trans-radial percutaneous coronary intervention (tr-pci) is rapidly becoming the gold standard. this is especially the case in primary percutaneous coronary interventions (pci), where most benefits of the radial approach, such as reduced major bleeding and mortality, can be expected. however there is very limited research available looking at the consequences of trans-radial access for upper extremity function. the main objective of this study is to provide insight in the morbidity with regards to the upper extremity surrounding the radial access route in percutaneous coronary interventions. secondary objectives are to provide insight in the consequences for functional status, factors influencing and financial costs of this morbidity, to identify subject who might benefit from early referral and treatment of this morbidity and to generate hypotheses for further clinical research into this matter. the investigators hypothesis is that approximately 20% of the population will experience upper extremity dysfunction after tr-pci.


Eligibility criteria:
inclusion criteria: * presenting for tr-pci at the study centre. * the radial artery can be palpated and doppler ultrasound examination of the radial artery shows non-occlusive flow. exclusion criteria: * currently enrolled in another study that clinically interferes with this study and that has not passed the primary endpoint. * the clinical condition prohibits or hinders informed consent and/or baseline examinations. e.g. cardiogenic shock and cardiopulmonary resuscitation or subconscious and semiconscious state,. * co-morbid condition(s) that could limit the subject's ability to participate in the study or to comply with follow-up requirements, or impact the scientific integrity of the study, e.g. loss of voluntary motor control of the studied extremities.

Keywords: upper extremity dysfunction trans-radial percutaneous coronary interventions
the desensitizing treatment effects of the laser and ozone on dentin hypersensitivity: in-vivo comparison

Conditions: Dentin Sensitivity

Summary: the goal of this split mouth clinical trial is to compare clinical efficacy of diode laser and gas ozone in the treatment of dentine hypersensitivity (dhs) of non-carious-cervical lesion. the main questions it aims to answer are: * gas ozone affects dentine hypersensitivity? * diode laser affects dentine hypersensitivity? participants, affected of dhs , were treated with gas ozone and diode laser.the pain severity was quantified according to the visual analogue scale (vas) before and after the treatmens.


Eligibility criteria:
inclusion criteria: * stimulated dentine hypersensitivity greater than 6 on visual analogue scale (vas) * dhs affected two teeth, not contiguous, of different mouth semiarch. exclusion criteria: * periodontal surgery in the last 3 month * use of desensitizing paste in the last 3 month * pregnant or breastfeeding state * teeth with caries, reconstructions, pulpits congenital anomalies, fracture, and occlusal interferences.
automated chest physiotherapy to improve outcomes in neuro

Conditions: Brain Injury; Intracranial Hypertension

Summary: following current standard-of-care, subjects data (brain pressure) will be recorded for 1 hour and include 10-minutes of data during which the subject recieves chest physiotherapy (cpt). the hypothesis is that cpt is not harmful to brain pressure.

the purpose of this study is to examine the effect of chest physiotherapy (cpt) on intracranial pressure (icp). because cpt is a normal part of the routine care provided to patients in the neurocritical care unit (ncu) this is an observational study of current practice. 1. the purpose of this study is to examine the effect of chest physiotherapy (cpt) on intracranial pressure (icp). because cpt is a normal part of the routine care provided to patients in the neurocritical care unit (ncu) this is an observational study of current practice. 2. the study will include only patients who currently have intracranial pressure monitoring devices in place (intraventricular and intraparenchymal). the study will last 1-hour and all subjects in the study will receive 10-minutes of cpt. the 10-minute cpt episode will be randomly assigned to occur 10, 20, 30 or 40-minutes into the study. 3. ancova using sas will be used to explore for within and between group differences in icp. this study observes current standard practice, there are no additional risks to the subject.

Eligibility criteria:
inclusion criteria: * documented episode of elevated icp icp monitoring in situ neurological/neurosurgical diagnosis currently on a specialy bed exclusion criteria: * spinal cord injury such that cpt is not desired

Keywords: brain injury intracranial hypertension human subjects nursing care
effect baroreflex activation therapy on the carotid body

Conditions: Hypertension Resistant To Conventional Therapy; Baroreflex; Carotid Body

Summary: carotid baroreflex activation therapy (bat) by the rheos® system produces a sustained fall in blood pressure in patients with resistant hypertension. since the activation electrodes are implanted at the level of the carotid sinus, it is conceivable that the nearby located carotid body chemoreceptors are stimulated as well. physiological stimulation of carotid chemoreceptors not only raises respiration, but it also increases sympathetic activity which may in part counteract the effects of bat. the aim of the present study is to investigate whether there is evidence for concomitant carotid chemoreflex activation during bat. we hypothesized that there is no clinically relevant co-activation of the carotid body chemoreceptors during bat in patients with resistant hypertension.


Eligibility criteria:
inclusion criteria: * be currently implanted with rheos system and have completed the 13-month follow-up period. * be on stable anti-hypertensive therapy for at least 4 weeks prior to inclusion, where stable is defined as no changes in medications or dosage of medications. * have at least one functional carotid baroreflex activation electrode. * have signed and approved informed consent form for participation in this study. exclusion criteria: * myocardial infarction (mi) or cerebral vascular accident (cva) within the past 90 days, or subject is still unstable from a prior mi or cva that occurred more than 90 days ago. * are unable or unwilling to comply with the protocol requirements of this study. * diagnosed with severe chronic obstructive lung disease (copd/asthma gold stadium iii and iv).

Keywords: baroreflex electrical stimulation carotid body chemoreceptors resistant hypertension
study of ono-8577 in patients with overactive bladder

Conditions: Overactive Bladder

Summary: the objective of the study is to evaluate the efficacy and safety of ono-8577 compared to combination of solifenacin succinate and mirabegron or placebo for overactive bladder


Eligibility criteria:
inclusion criteria: * patient with symptoms of overactive bladder for ≥6 months exclusion criteria: * patient with genuine stress incontinence, or with stress-predominant mixed urinary incontinence * patient who has never experienced urge urinary incontinence during disease duration of overactive bladder
relationships among fviii, t-pa/pai-1, and mmp-9 levels and intracranial hemorrhage complications after thrombolysis with alteplase in patients with acute ischemic stroke: protocol for a multicenter retrospective study

Conditions: Ischemic Stroke

Summary: the primary aim of the study is to investigate the relationships among fviii, t-pa/pai-1, mmp-9 levels, and intracranial hemorrhage after thrombolysis with alteplase using a combined analysis.

patients with acute ischemic stroke treated with alteplase within 4.5 hours after the onset of stroke symptoms will be recruited in this study. all participants will be divided into two groups according to whether intracranial hemorrhage occurred within 3 days after treatment with alteplase for analysis. differences in fviii, t-pa/pai-1, and mmp-9 levels before and after thrombolytic therapy will be examined in both groups. this study will be conducted at zhujiang hospital of southern medical university, nanfang hospital of southern medical university, and the first affiliated hospital of jinan university.

Eligibility criteria:
inclusion criteria: * diagnosis of ischemic stroke and within the time window of thrombolysis (onset of symptoms no more than 4.5 hours ) * 18 y age 85 y• * symptoms of neurological deficits caused by cerebral infarction * informed consent form to confirm thrombolytic therapy have signed by patients or their family. exclusion criteria: * a history of major head trauma or stroke in the past 3 months * suspicious subarachnoid hemorrhage * arterial puncture at noncompressible site in the last week * history of intracranial hemorrhage * intracranial neoplasm, arteriovenous malformation, or aneurysm * recent intracranial or intraspinal surgery * elevated blood pressure (systolic \>185 mm hg or diastolic \>110 mm hg) * active internal bleeding or acute bleeding diathesis * platelet count \<100×109·l-1 * heparin received within 48 h resulting in aptt above the upper limit of normal * current use of anticoagulant with inr \>1.7 or pt \>15 s * current use of thrombin inhibitors or factor xa inhibitors * abnormal laboratory tests (eg, aptt, inr, platelet count, ect, tt, or appropriate factor xa activity assays) * blood glucose concentration \> 2.7 mmol/l * ct demonstrates multilobar infarction (hypodensity \>1/3 cerebral hemisphere) * mild cerebral infarction or rapid improvement of symptoms of cerebral infarction * symptoms of neurological impairment after seizures * major surgery or severe trauma in the past 2 weeks * gastrointestinal or urinary bleeding in the past 3 weeks * history of myocardial infarction in the past 3 months * combine diseases that may affect outcomes,such as anemia, hemophilia * history of autoimmune disease or organ transplantation * pregnancy or breastfeeding women

Keywords: t-pa/pai-1 mmp-9 fviii alteplase intracranial haemorrhage ischemic stroke
balloon angioplasty for intracranial atherosclerotic minor stroke/tia

Conditions: Ischemic Stroke

Summary: the objective of this study was to evaluate the safety and efficacy of early submaximal balloon angioplasty combined with medical therapy vs medical therapy alone for minor stroke/transient ischemic attack with intracranial atherosclerosis etiology.

in this study, 416 patients with minor strokes or transient ischemic attacks due to symptomatic intracranial atherosclerotic stenosis within one week of the onset of last ischemic symptoms from 20 centers in china were enrolled. the observation group received early submaximal balloon angioplasty, while the control group received only medical therapy. two groups will be followed up for 1 year to evaluate the safety and efficacy of early submaximal balloon angioplasty combined with medical therapy vs medical therapy alone for minor stroke / transient ischemic attack with intracranial atherosclerosis etiology.

Eligibility criteria:
inclusion criteria: 1. age range of 30-80 years; 2. symptomatic icas (c4-c7 segments of ica, m1 segment of the mca, v4 segment of the va, and ba) with 70%-99% stenosis confirmed by dsa; 3. minor stroke (nihss score ≤5) within 1 week of onset or from symptom exacerbation (nihss score increased by ≥2 points) or intermediate- to high-risk tia, defined as abcd2 score ≥4 within 1 week of the last symptom episode; 4. diameter of the culprit artery ranging from 2.0 to 4.5mm, and the length of the stenosis≤14mm; 5. mrs ≤ 2 before endovascular treatment； 6. no large ischemic region found on ct or mri (aspects≥ 6 or pc-aspects ≥8)； 7. written informed consent obtained from the patient or legally responsible person. exclusion criteria: 1. allergy to contrast media; 2. non-atherosclerotic disease-related stenosis, such as arterial dissection, moya-moya disease, and arteritis; 3. penetrating branch lesion ipsilateral to the target lesion (infarction caused by penetrating branch occlusion is defined as stenosis of the mca or ba, but only with simple basal ganglia or brainstem/thalamic infarction); 4. presence of severe stenosis of the extracranial segment on the side of the target lesion; 5. previous endovascular treatment of the ipsilateral vessel; 6. presence of intracranial aneurysms, tumors, and vascular malformations; 7. any form of ipsilateral intracranial hemorrhage within 3 months and contralateral intracranial hemorrhage within 2 weeks; 8. presence of atrial fibrillation, severe heart dysfunction, liver or kidney dysfunction; patients with tumors and serious diseases whose expected survival time is ≤ 1 year; 9. hemoglobin ≤ 100g/l, platelet count ≤ 100×10\^9/l, inr\> 1.5 (irreversible), coagulopathy or irremediable bleeding factors; 10. uncontrollable hypertension: systolic blood pressure \>185 mmhg and/or diastolic blood pressure \>110 mmhg; 11. poor glycemic control (random blood glucose \> 22.2 mmol/l); 12. history of major surgery within 30 days prior to enrollment or surgery plan within 90 days after enrollment; 13. pregnancy or lactation; 14. other conditions that the researchers think make the patient unsuitable for the study.
ultrasound guided axillary versus jugular central venous catheterization

Conditions: Critical Illness

Summary: the main intention of this study is to compare two ultrasound-guided central venous catheterization procedures namely: real-time, ultrasound-guided, in plane axillary vein catheterization and real-time, ultrasound-guided, out of plane jugular vein catheterization in terms of venipuncture, catheterization success, early mechanical complication and catheter-related infection rate in mechanically ventilated patients admitted to the intensive care unit.


Eligibility criteria:
inclusion criteria: * mechanically ventilated intensive care patients with clinical indications for central venous line placement exclusion criteria: * trauma and hematoma at the catheterization site * major blood coagulation disorders coincided with active bleeding * anatomical abnormalities at the catheterization site * infection at the catheterization site * age less than 18 years * lack of patients or closest relatives consent

Keywords: ultrasonography catheterization central line mechanical ventilation intensive care axillary vein jugular vein randomization
a global study to assess the effects of medi4736 (durvalumab) in patients with locally advanced or metastatic non small cell lung cancer

Conditions: Non-Small Cell Lung Cancer

Summary: a study to assess the effects of medi4736 (durvalumab) in patients with locally advanced or metastatic non small cell lung cancer in terms of efficacy, safety and tolerability

this study is designed to investigate the efficacy, safety, tolerability of a new drug, medi4736 (durvalumab), in patients with locally advanced or metastatic non small cell lung cancer. medi4736 will be investigated in patients who have received at least two prior treatment regimens including one platinum-based chemotherapy

Eligibility criteria:
inclusion criteria: * aged at least 18 years. * documented evidence of nsclc (stage iiib/iv disease) * disease progression or recurrence after both a platinum-based chemotherapy and at least 1 additional regimen for treatment of nsclc * world health organisation (who) performance status of 0 or 1 * estimated life expectancy of more than 12 weeks * patient's tumour sample must be pd-l1 positive (≥25%of tumour cells with membrane staining (cohort 1 and 2) or pd-l1 positive with ≥90% of tumour cells with membrane staining (cohort 3)) exclusion criteria: * prior exposure to any anti-pd-1 or anti-pd-l1 antibody * brain metastases or spinal cord compression or unless asymptomatic, treated and stable (not requiring steroids). * active or prior autoimmune disease or history of immunodeficiency * evidence of severe or uncontrolled systemic diseases, including active bleeding diatheses or active infections including hepatitis b, c and hiv. * evidence of uncontrolled illness such as symptomatic congestive heart failure, uncontrolled hypertension or unstable angina pectoris. * any unresolved toxicity ctcae \>grade 2 from previous anti-cancer therapy. * any prior grade ≥3 immune-related adverse event (irae) while receiving any previous immunotherapy agent, or any unresolved irae \>grade 1 * active or prior documented inflammatory bowel disease (eg, crohn's disease, ulcerative colitis)

Keywords: locally advanced, metastatic, non-small cell lung cancer, medi4736, durvalumab, pd-l1
chronic pain after shoulder arthroplasty

Conditions: Chronic Pain

Summary: chronic pain is relatively common after different types of surgery. the investigators intend to study prevalence, characteristics and risk factors of chronic pain after shoulder arthroplasty, focusing on neuropathic pain characteristics, and risk factors such as preoperative pain, severe acute postoperative pain, age, gender, and pain elsewhere.


Eligibility criteria:
inclusion criteria: * patients operated with any shoulder prosthesis between april 2011 and april 2012 in denmark exclusion criteria: * secondary prosthesis * bilateral prosthesis * age below 18 * reoperated in the same shoulder after the prosthesis
qt intervals study to compare the acute effects of orally inhaled dihydroergotamine (dhe), oral moxifloxacin, and placebo

Conditions: Healthy

Summary: compare the acute effect on the qt interval of map0004 (dihydroergotamine mesylate delivered by oral inhalation) with moxifloxacin and placebo.


Eligibility criteria:
inclusion criteria: 1. able to provide a signed, executed written informed consent 2. healthy non-smoking adult volunteers: male or female subjects 18 to 45 years old 3. female subjects who are practicing adequate contraception (see section 4.4) or who are sterile 4. no known cardiac disease 5. normal hemoglobin values 6. normal or not clinically significant 12-lead electrocardiogram * heart rate ≥ 40 and ≤ 100 at visit 1 vital signs assessment (resting) * subjects with qtcf interval duration \<430 msec for males and \<450 msec for females obtained from the ecg recorder's measurements on the screening ecg taken after at least 5 minutes of quiet rest in supine position 7. demonstrated ability to properly use the tempo® inhaler 8. subject has not donated blood in the last 56 days exclusion criteria: 1. contraindication to dihydroergotamine mesylate (dhe) 2. history of hemiplegic or basilar migraine 3. family history of long qt syndrome 4. participation in another investigational trial during the 30 days prior to visit 1

Keywords: healthy volunteers
real-world effectiveness of dupilumab in patients with prurigo nodularis: an observational study

Conditions: Prurigo Nodularis

Summary: this study is a prospective, multinational, observational investigation designed to elucidate the real-world effectiveness and treatment patterns of dupilumab therapy in adult patients diagnosed with prurigo nodularis (pn). the primary objective of this study is to comprehensively characterize the real-world usage of dupilumab for the management of pn. in addition to this, the study aims to achieve several secondary objectives, including a detailed assessment of the medical history, socio-demographic and disease characteristics of dupilumab-treated pn patients, as well as the evaluation of the long-term real-world effectiveness of dupilumab therapy for pn.

the follow-up period will be 36 months or until death, loss to follow-up, or withdrawal, whichever comes first.

Eligibility criteria:
inclusion criteria: * patients aged 18 years or older at the time of informed consent. * physician decision to treat the patient with dupilumab for prurigo nodularis (according to the country-specific prescribing information) made prior to and independently of the patient's participation in the study. * patients able to understand and complete study-related questionnaires. * patients provide voluntary informed consent to participate in the study before inclusion in the study. exclusion criteria: * patients who have a contraindication to dupilumab according to the country-specific prescribing information label. * any condition that, in the opinion of the investigator, may interfere with the patient's ability to participate in the study, such as short life expectancy, substance abuse, severe cognitive impairment, or other comorbidities that can predictably prevent the patient from completing the schedule of visits and assessments. * patients currently participating in any interventional clinical trial. * prior use of dupilumab within 6 months of the screening visit, or within 6 months of the baseline visit if screening and baseline occur on the same day.